Phospho-AURKA (Thr288) Antibody

What is Aurora A kinase and what is the significance of Thr288 phosphorylation?

Aurora A (AURKA) is a serine/threonine kinase that regulates mitosis through its association with centrosomes. It belongs to the Aurora kinase family, which includes Aurora A, B, and C. Aurora A plays a critical role in cell cycle regulation, particularly during anaphase and telophase, controlling centrosome/spindle pole function during chromosome segregation .

The phosphorylation of Aurora A at Threonine 288 (Thr288) represents a key activation mechanism. This autophosphorylation primarily occurs from late S-phase through M phase during the cell division cycle or in response to DNA damage. Thr288 phosphorylation is essential for the full catalytic activation of Aurora A's kinase activity .

Aurora A is highly expressed in testis and weakly expressed in skeletal muscle, thymus, and spleen. Notably, overexpression of Aurora A is observed in many cancer types including breast, ovarian, and colorectal cancers, making it a potential target for anticancer drug development .

How does the Phospho-Aurora A (Thr288) antibody work in detecting Aurora A activation?

Phospho-Aurora A (Thr288) antibodies specifically recognize and bind to Aurora A protein only when phosphorylated at the Threonine 288 residue. This specificity allows researchers to distinguish between inactive and active forms of the protein .

In techniques like HTRF (Homogeneous Time-Resolved Fluorescence), detection involves two labeled antibodies: one with a donor fluorophore and another with an acceptor. The first antibody binds specifically to the phosphorylated Thr288 motif, while the second recognizes the Aurora A protein regardless of its phosphorylation state. When both antibodies bind to the same protein molecule, the proximity generates a FRET signal proportional to the concentration of phosphorylated Aurora A present in the sample .

In Western blotting applications, the antibody directly binds to phosphorylated Thr288 sites on Aurora A proteins separated by gel electrophoresis and transferred to a membrane, then visualized using secondary detection methods .

What cell lines are suitable for Aurora A (Thr288) phosphorylation studies?

Several human cell lines have been validated for Aurora A (Thr288) phosphorylation studies, each with specific characteristics:

Cell density optimization is crucial for each cellular model to ensure measurements fall within the detection method's dynamic range. Phosphorylated Aurora A (Thr288) protein is detectable in all these human cell lines, though at different levels .

How does cell cycle phase affect Aurora A phosphorylation at Thr288?

Aurora A phosphorylation at Thr288 is tightly regulated throughout the cell cycle. The phosphorylation primarily occurs from late S-phase through M phase during the cell division cycle .

During the G2/M transition and M phase, Aurora A becomes activated through autophosphorylation at Thr288, enabling its functions in centrosome maturation, centrosome separation, and spindle assembly. As cells exit mitosis, Aurora A is dephosphorylated and subsequently degraded .

Experimental evidence shows that treatments inducing G2/M cell cycle arrest, such as Nocodazole (a microtubule destabilizer), lead to increased levels of both total Aurora A protein and Thr288-phosphorylated Aurora A. This increase helps cells overcome cell cycle arrest . This property is frequently exploited in laboratory settings when studying Aurora A, as researchers often use Nocodazole treatment to enhance Aurora A expression and phosphorylation for easier detection.

What are the main applications of Phospho-Aurora A (Thr288) antibody in research?

Phospho-Aurora A (Thr288) antibodies serve multiple critical functions in cancer research and cell biology:

These antibodies enable researchers to detect endogenous levels of phosphorylated Aurora A protein and quantitatively assess changes in Aurora A activation in response to various treatments or genetic manipulations .

How can I optimize experimental conditions for detecting Aurora A Thr288 phosphorylation in different cancer cell lines?

Optimizing experimental conditions for Aurora A Thr288 phosphorylation detection requires careful consideration of several parameters:

Cell Density Optimization:
Different cell lines express varying levels of Aurora A protein, necessitating optimization of cell density:

• For high Aurora A expressors like HepG2, use lower densities (25,000 cells/well or below)

• For HeLa, HEK293, or HCT116, densities between 25,000 to 100,000 cells/well are suitable

• Perform a cell density titration experiment to determine the optimal range for your specific cell line

Cell Cycle Synchronization Protocol:

• Seed HeLa cells at 100,000 cells/well for 24 hours in complete culture medium

• Remove medium and treat with 200-300 nM Nocodazole for 20 hours to induce G2/M arrest

• This enhances Aurora A phosphorylation for more robust detection

Optimized Lysis Procedure:

• Remove culture medium completely

• Add 50 μL of supplemented lysis buffer per well (96-well format)

• Lyse cells for 30 minutes at room temperature under gentle shaking

• For HTRF detection, transfer 16 μL of lysate to a 384-well low volume plate

This optimization approach ensures consistent and reliable detection of phosphorylated Aurora A across different experimental systems.

What are the advantages and limitations of using HTRF vs Western Blot for Phospho-Aurora A (Thr288) detection?

Comparing these two commonly used techniques reveals significant differences in sensitivity, throughput, and application:

A side-by-side comparison demonstrated that the HTRF assay is 2-fold more sensitive than Western Blot for detecting phosphorylated Aurora A under the tested experimental conditions . For conclusive studies, using both techniques provides complementary information.

How can I validate the specificity of Phospho-Aurora A (Thr288) antibody in my experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For Phospho-Aurora A (Thr288) antibodies, implement these validation approaches:

siRNA Knockdown Protocol:

• Transfect cells with 25 nM siRNA specifically targeting Aurora A (e.g., SMARTPool ON-TARGETplus siRNA)

• Include non-targeting siRNA as negative control

• After 24h, stimulate with 300 nM Nocodazole for additional 24h

• Lyse cells and assess phospho-signal

• Expected outcome: ~57% signal decrease in Aurora A siRNA-treated cells compared to control

Aurora Kinase Inhibitor Treatment:

• Treat cells with specific Aurora A inhibitors (MLN8054, Tozasertib, or Alisertib)

• Co-incubate with 200 nM Nocodazole for 20h to enhance baseline phosphorylation

• These inhibitors should reduce Thr288 phosphorylation without affecting total Aurora A levels

• Observe dose-dependent inhibition of phosphorylation

These validation steps provide confidence in the specificity of the Phospho-Aurora A (Thr288) antibody and strengthen the reliability of experimental findings.

What are the best methods for quantifying changes in Aurora A Thr288 phosphorylation in response to potential inhibitors?

Quantifying inhibitor effects on Aurora A Thr288 phosphorylation requires systematic approaches:

HTRF-Based Inhibitor Profiling Protocol:

• Seed HeLa cells at 100,000 cells/well for 24 hours

• Co-treat with inhibitor (serial dilutions) and 200 nM Nocodazole for 20 hours

• Remove medium, add 50 μL supplemented lysis buffer for 30 minutes

• Transfer 16 μL lysate to 384-well plate, add 4 μL HTRF detection antibodies

• Incubate overnight and measure FRET signal

• Calculate percent inhibition relative to Nocodazole-only treated controls

Inhibitor Selectivity Assessment:

• Simultaneously measure Aurora A (Thr288) and Aurora B (Thr232) phosphorylation

• Compare inhibition profiles across Aurora family members

• Known inhibitor profiles based on literature:

  • MLN8054: More selective for Aurora A

  • Tozasertib: Inhibits both Aurora A and B

  • Alisertib: Aurora A-selective inhibitor

Three reference compounds (MLN8054, Tozasertib, Alisertib) demonstrated clear dose-dependent inhibition of Aurora A phosphorylation at Thr288, reaching up to 98% maximum inhibition, without impacting the total protein level .

How can I distinguish between Aurora A and other Aurora kinase family members when assessing phosphorylation states?

Distinguishing between Aurora kinase family members requires specific strategies:

Phosphorylation Site-Specific Detection:

• Aurora A is phosphorylated at Thr288

• Aurora B is phosphorylated at Thr232

• Use antibodies specifically validated against each phosphorylation site

Parallel Detection Protocol:

• Split identical samples into separate detection wells

• Probe with:

  • Phospho-Aurora A (Thr288) antibodies

  • Total Aurora A antibodies

  • Phospho-Aurora B (Thr232) antibodies

  • Total Aurora B antibodies

• Compare inhibition patterns across family members

siRNA-Based Validation:

• Perform selective knockdown using siRNAs specific to:

  • Aurora A (e.g., ON-TARGETplus siRNA #L-003545-01-0005)

  • Aurora B (e.g., ON-TARGETplus siRNA #L-003326-00-0005)

  • Aurora C (e.g., ON-TARGETplus siRNA #L-019573-00-0005)

• Include non-targeting siRNA control

• Assess effects on phosphorylation signal to confirm antibody specificity

These approaches enable confident distinction between Aurora kinase family members and accurate characterization of inhibitor specificity.

What control treatments should be included when studying Aurora A phosphorylation?

Comprehensive controls are essential for experimental validity when studying Aurora A phosphorylation:

The search results indicate that HeLa cells treated with Aurora A siRNA showed a significant downregulation of Aurora A, with a 57% signal decrease compared to cells transfected with non-targeting siRNA . These controls ensure robust experimental design and confident result interpretation.

What are the challenges in detecting endogenous levels of phosphorylated Aurora A protein?

Detecting endogenous phosphorylated Aurora A presents several technical challenges:

Cell Cycle-Dependent Expression:

• Aurora A phosphorylation at Thr288 primarily occurs during late S-phase through M-phase

• In asynchronous populations, only a small fraction of cells have detectable phosphorylation

• Solution: Use Nocodazole treatment (200-300 nM for 20 hours) to enrich for G2/M phase cells

Cell Line Variability:

• Different cell lines express varying levels of Aurora A protein:

  • HepG2: Higher expression (use 25,000 cells/well or below)

  • HeLa, HEK293, HCT116: Moderate expression (25,000-100,000 cells/well suitable)

• Solution: Optimize protocols for each cell line with appropriate cell density

Sensitivity Requirements:

• Western blot may lack sensitivity for detecting low phosphorylation levels

• Solution: Consider HTRF methods which can be 2-fold more sensitive

For the most robust detection, the HTRF Phospho-Aurora A (Thr288) assay efficiently detects endogenous phosphorylated Aurora A protein across various human cellular models expressing different levels of the protein .

How do inhibitors affect Aurora A phosphorylation compared to total protein levels?

Understanding how inhibitors differentially affect phosphorylation versus total protein levels is crucial for mechanism studies:

Experimental Evidence from Inhibitor Studies:

• HeLa cells were treated with increasing concentrations of inhibitors (MLN8054, Tozasertib, or Alisertib) co-incubated with 200 nM Nocodazole for 20h

• Both phosphorylated and total Aurora A were measured using specific antibodies

• Results showed clear dose-dependent inhibition of Aurora A phosphorylation at Thr288 upon treatment with all three inhibitors

• Critically, the Aurora A protein expression level remained constant throughout the experiment

This differential effect (inhibition of phosphorylation without changing total protein levels) confirms that these compounds act by preventing phosphorylation rather than by reducing protein expression. This mechanistic insight is important for understanding how Aurora kinase inhibitors function and for developing new therapeutic approaches targeting this pathway .